In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that  non-dilutive funding is becoming increasingly available for innovative medical device companies.

The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work, all the way to late stage clinical research and validation.

In this webinar, FreeMind experts will discuss the latest trends at the NIH and the funding opportunities available with respect to medical devices.

Non-US applicants are eligible for the majority of the non-dilutive funding sources, including the National Institutes of Health (NIH), the US Department of Defense, and BARDA to name a few. Currently, the NIH are actively funding over over $1.3B for over 1,000 projects taking place outside the US and awarded to non-US applicant organizations. When taking into account collaboration and partnerships between US and non-US into entities, the funded R&D dollars for projects outside the US are even higher.

In this presentation, we will provide insight into the non-dilutive funding landscape for non-US based companies, with an emphasis on the NIH, Department of Defense and other government agencies. FreeMind experts will describe the various pockets of money available for non-US applicants, potential for funding, and means to maximize chances for award.